PREVAIL: A phase 3 trial of enzalutamide after
i
ADT i
ith CRPC
Co‐primary endpoints:
progress on on
n men w m
•
OS
•
rPFS
Enzalutamide
160 mg/day
(capsules)
n=872
R
A
Patient
p
opulation:
•
1717 men with progressive mCRPC
•
Asymptomatic/
mildly symptomatic
N
D
O
M
I
•
Chemotherapy‐naïve
•
Steroids allowed but not required
Z
E
D
Placebo
n=845
1:1
Beer T, et al. NEJM 2014
